Hims & Hers Health (HIMS) lays off 4% of its workforce as the company adjusted its strategy amid FDA scrutiny on copycat ...

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

It is the biggest shake-up of obesity treatment in NHS history, it has been claimed. From later this month, GPs will be able ...

Hims Hers Health Inc (NYSE:HIMS), a telehealth firm known for offering consumer-focused digital healthcare, is reducing its headcount by more than 4% as part of a pivot in its business strategy, ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

We recently published a list of Investors Rushed Into These 10 Stocks Today. In this article, we are going to take a look at ...

Japan’s foray into regenerative medicine takes on added importance for a nation wrestling with age, stagnation, and its place ...

The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...